The VTT Technical Research Centre of Finland and Bayer Schering Pharma AG, Germany have signed a two-year research cooperation contract for developing new cancer drugs. The new project is a continuation of similar cooperation, which ended last year.
In the research, VTT will utilise newly developed 3D cancer cell culturing model that enables the study of the cells in an environment that better resembles the conditions in the human body. The model also allows for improved analyses on the invasive and metastatic behaviour of cancer cells. Through this model, VTT scientists can better predict the growth controlling properties of the drugs which are being developed.
The Project Leader, VTT's Senior Research Scientist, Marko Kallio says that while investing heavily on top research and technology VTT has become a leading specialist in the field of molecular cancer research. Through the new project VTT aims to increase the impact of its expertise on the international pharmaceutical sector.
VTT's Medical Biotechnology knowledge centre focuses on identifying factors connected to the onset mechanism and spreading of cancer. The unit also works to find small molecule inhibitors that prevent the growth and metastasis of various types of cancer. In addition, it develops and utilises versatile recombinant antibody methods and plant biotechnology tools for the needs of pharmaceutical and food industries.